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Abstract. Osteoarthritis (OA) is a chronic disorder of synovial 
joints, in which there is progressive softening and disinte-
gration of the articular cartilage. OA is the most common 
form of arthritis, and is the primary cause of disability and 
impaired quality of life in the elderly. Despite considerable 
medical necessity, no treatment has yet been proven to act 
as a disease-modifying agent that may halt or reverse the 
structural progression of OA. The replacement of the joint 
with a prosthesis appears to be the best option in the advanced 
stages of the disease. A formulation (BIOF2) for cartilage 
regeneration has been recently developed. The present study 
evaluated the effects of BIOF2 on gene expression in human 
cell cultures, followed by efficacy trials in three OA animal 
models. Human synovial fluid cells that were exposed to the 
formulation exhibited increased transcription factor SOX-9 
(SOX9; chondrogenic factor) expression, and decreased 
mimecan (mineralization inducer) and macrophage-stimu-
lating protein receptor (osteoclastogenic factor) expression. 
The intra-articular application of BIOF2 in the animal models 
significantly increased cartilage thickness from 12 to 31% at 
28 days, compared with articular cartilage treated with saline 
solution. The articular area and number of chondrocytes 
additionally increased significantly, maintaining an unaltered 
chondrocyte/mm2 proportion. Evaluation of the histological 
architecture additionally displayed a decrease in the grade 
of articular damage in the groups treated with BIOF2. In 
conclusion, BIOF2 has proven to be effective for treating OA 
in animal models, most likely due to SOX9 overexpression in 
articular cells.
Introduction
Osteoarthritis (OA) is a chronic disorder of synovial joints, 
in which there is progressive softening and disintegration of 
articular cartilage accompanied by other alterations, including 
osteophyte growth, cyst formation and subchondral scle-
rosis (1). It is the most common form of arthritis, and is the 
primary cause of disability and impaired quality of life in the 
elderly (2). By the age of 65, ~80% of the population is likely 
to suffer from this disease (3), and the knee joint is the most 
frequently affected. No treatment, despite considerable medical 
necessity, has yet been proven to act as a disease-modifying 
agent that may halt or reverse the structural progression of 
OA. Apart from lifestyle modifications, the only available 
non-surgical treatments are directed at symptoms, primarily 
to alleviate pain and improve quality of life (4).
In cases of advanced disease, a recommended option is 
total joint arthroplasty (TJA), replacing the articulation with 
a prosthesis. However, such surgical treatment is costly (5), 
and frequently there is a long waiting list. Although the risk 
of serious adverse events following TJA is low, perioperative 
risks may be high in elderly patients or in those with comor-
bidities. Long-term progression may be considered in patients 
with a prolonged life expectancy (6).
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In recent years, the aforementioned issues have provoked 
a search for novel drug therapy regimens. In addition to 
pain management through antidepressants, nonsteroidal 
anti‑inflammatory drugs or opiates, the oral administration of 
other substances, including glucosamine, chondroitin sulfate, 
methylsulfonylmethane or collagen hydrolysates, has been 
studied, demonstrating limited or no benefit. Intra‑articular 
injections of different substances, including hyaluronic acid 
derivatives or platelet-rich plasma, are being evaluated (7). 
Stem cell and gene therapy are additional strategies that are 
currently in development (8,9).
An innovative concept is the creation of novel cartilage 
in a damaged joint through the administration of bioactive 
substances that promote chondrogenesis. This idea is based on 
the fact that the fluid inside the joint contains mesenchymal 
cells (MSCs) that are able to differentiate into chondrocytes (9). 
Corticosteroids are one such bioactive substance. When acting 
alone, corticosteroids may facilitate tissue atrophy and joint 
destruction; however, when acting in synergy with other 
factors, they have been demonstrated to increase a number of 
chondrogenic markers (10), in addition to aiding in the accu-
mulation of extracellular matrix, which is necessary for the 
formation of cartilage (11). In addition, substances that contain 
insulin or certain organic acids favor chondrogenesis (12-14).
A formulation for the regeneration of cartilage has recently 
been developed (15). It is composed of a corticosteroid, insulin 
and organic acids. The intra-articular application of this 
bioactive formulation, termed BIOF2 in the present study, is a 
promising strategy to alleviate and reverse the adverse effects 
of OA. The present study evaluated the effects of BIOF2 on 
gene expression in human cell cultures, followed by efficacy 
trials in in vivo models.
Materials and methods
BIOF2. The formulation BIOF2 was provided by Esteripharma 
México S.A de C.V., Ciudad de México, México.
Effect of BIOF2 on gene expression in human synovial fluid 
cells. Synovial fluid cells were isolated from a sample from the 
knee of a 58 years old Mexican women with OA who underwent 
articular lavage as part of her treatment in the Clínica-Hospital 
Unión in Villa de Álvarez, Colima, México on November, 
2015. The patient voluntarily donated the sample and signed 
a statement of informed consent. A total of 200 µl synovial 
fluid was incubated in Dulbecco's modified Eagle's medium 
(DMEM; Gibco; Thermo Fisher Scientific, Inc., Waltham, 
MA, USA) supplemented with 10% fetal bovine serum (FBS; 
Gibco; Thermo Fisher Scientific, Inc.) and 1% penicillin/strep-
tomycin (PS) in a 25 cm2 (T‑25) cell culture flask, in a 5% 
CO2 atmosphere at 37˚C for 24 h. Washes with sterile 1X PBS 
(pH 7.4; Gibco; Thermo Fisher Scientific, Inc.) were performed 
to remove unattached cells, and DMEM supplemented with 
10% FBS and 1% PS was added. Cells were cultured until cell 
outgrowths were well-established. At passage 3, the cells were 
morphologically homogeneous and exhibited the appearance 
of fibroblast‑like synoviocytes, with the typical bipolar config-
uration visible under inverse microscopy. Following the same 
methodology, a previous report stated that >98% of the cells 
obtained expressed surface markers for fibroblasts (16). Low 
passage (3‑6) cell stocks were maintained at ‑70˚C. To perform 
the differential expression experiment, cells were seeded 
in two T‑25 flasks in DMEM supplemented with 10% FBS. 
When the cells covered 80% of the flask surface, the medium 
was substituted with supplemented DMEM (1% FBS). BIOF2 
was added to one flask (5%) and the other flask was used as a 
reference. The cells were removed 48 h subsequently for RNA 
extraction and to verify the alterations in expression caused by 
BIOF2 in certain genes of interest.
Total RNA was extracted from the cells using TRIzol® 
reagent (Thermo Fisher Scientific, Inc.), according to the 
manufacturer's protocol. Subsequently, 50 ng total RNA was 
subjected to a one-step reverse transcription-quantitative poly-
merase chain reaction (RT-qPCR) using the SuperScript® III 
Platinum® SYBR® Green One‑Step RT‑qPCR kit (Invitrogen; 
Thermo Fisher Scientific, Inc.). qPCR was performed using 
the Roche Light Cycler version 1.5 (Roche Applied Science, 
Penzberg, Germany). The reaction was performed as follows: 
3 min at 50˚C, 5 min at 95˚C, and 40 cycles (15 sec at 95˚C, 
30 sec at 60˚C and 60 sec at 95˚C), followed by 1 min at 40˚C. 
Previously described primers were used to amplify GAPDH, 
macrophage-stimulating protein receptor (MST1R), transcrip-
tion factor SOX-9 (SOX9), neurogenic locus notch homolog 
protein 2 (NOTCH2), and mimecan (OGN) (17-21). The 
human housekeeping gene, GAPDH, was used for internal 
normalization. To determine the relative expression of the 
mRNAs, qPCR data were analyzed using the comparative 
ΔΔCq method, as previously described (22). All data were 
expressed as a relative fold difference compared with the 
expression in cells unexposed to BIOF2. RT-qPCR analysis 
was performed in quadruplicate.
OA animal model evaluation. The new formulation, BIOF2, 
was evaluated for the treatment of OA of the knee in three 
animal models. A total of two models were created via 
intra-articular injection of papain in young animals (BALB/c 
mice and Californian rabbits). The third model consisted of 
an advanced-age BALB/c mice. This type of mouse has been 
reported to spontaneously produce OA. Only male animals 
were used, since it is known that sex hormones serve an impor-
tant role in the development of OA, with female hormones 
acting as a protective factor and male hormones exacerbating 
the disease (23).
Papain‑induced OA mouse model. Male BALB/c mice 
(Envigo, Huntingdon, UK), between 8 and 10 weeks of age 
and initially weighing 25-28 g, were used in the present study. 
The mice were divided into two groups of 23 animals/group. 
The two groups had intra-articular papain administration to 
the right knee through the patellar ligament, with a 10 µl solu-
tion of papain, as has previously been described (24). Papain 
(type IV, double crystallized; 15 U/mg; Sigma‑Aldrich; Merck 
KGaA, Darmstadt, Germany) was used at a concentration of 
2.0% (w/v) and supplemented with 0.03 M L-cysteine HCI 
(Sigma‑Aldrich; Merck KGaA). A total of 3 weeks subse-
quently, 10 µl BIOF2 was administered to the experimental 
group and 10 µl sterile saline solution was administered to the 
control group. The two groups received intra-articular admin-
istration to the right knee. A total of 8 mice from each group 
were sacrificed on day 7 following BIOF2 injection, followed 
MOLECULAR MEDICINE REPORTS  17:  3503-3510,  2018 3505
by 7 mice from each group on day 14, and 8 mice from each 
group on day 28. The right knees were removed and processed 
for histopathological analysis.
Papain‑induced OA rabbit model. A total of eight 4-month-old 
Californian rabbits were included in the present study (initially 
weighing 2.8‑3.3 kg). The knee joints were subjected to an 
intra-articular injection of a 500 µl solution of papain through 
the patellar ligament, as described above. A total of 21 days 
following the application of papain, the right knee was subjected 
to an intra-articular injection of 500 µl BIOF2 through the 
patellar ligament and the left knee joint was injected with 
500 µl saline solution. All the rabbits that received the new 
formulation were sacrificed on day 28 following treatment, 
and the knees were histologically analyzed.
Spontaneous OA mouse model. A total of 16 18-month-old 
BALB/c mice were included (initially weighing 30-34 g). 
This strain of mouse has been reported to present sponta-
neous osteoarthritis starting at 12 months of age. However, 
the histological alterations have been reported to present 
variations from one joint to another and from one individual 
to another (25). Therefore, as it was not known which joint of 
which mouse may be more damaged, intra-articular injection 
of the new formulation into the two knees of the 8 mice in 
the experimental group was decided upon. Saline solution was 
injected into the two knees of each mouse in the control group, 
containing 8 mice. Intra-articular application was performed 
as in the mouse model described above. A total of 28 days 
following treatment, the mice were euthanized and the knees 
were histologically analyzed.
The mice were housed in cages, with a maximum of 
5 mice/cage. The mice were fed a standard diet (2018S Tekland 
Global 18% Protein Rodent Diet; Envigo). The rabbits were 
housed in individual cages and fed a standard diet (Tekland 
8630 Rabbit Diet; Envigo). Light (12‑h light/dark cycle), 
temperature (23˚C) and humidity (50%) were controlled for all 
the animals and they had access to food and water ad libitum. 
The animals were sacrificed via sodium pentobarbital 
overdose.
Histopathological analysis. The knee joints were dissected 
simultaneously and were fixed in solutions of 10% formalde-
hyde for 5 days at 24˚C, and subsequently decalcified in 5% 
formic acid for 4 days. The specimens were dehydrated in 
ethanol, embedded in paraffin wax, sectioned (5‑µm thick), 
and stained at 24˚C for 5, 2 and 1 min, respectively with hema-
toxylin/eosin and toluidine blue. As the degree of toluidine 
blue staining is influenced by variables, including staining 
time, all samples were sectioned and stained using stringent 
protocols to minimize variability. Images of the mouse 
femoral weight-bearing cartilage were captured. The slices 
were evaluated via images captured with an Axiocam MRC-5 
model digital camera (Zeiss GmbH, Jena, Germany) attached 
to an AxioPlan 2 M model bright field optical microscope 
(Zeiss GmbH) with a motorized stage and A-plan x5, x10 
and x40 objectives (total magnification, x50 for the rabbit 
cartilage and x100/x400 for the mouse cartilage). Images of 
the entire sample surfaces were scanned using the Mosai X 
and Autofocus modules. All images were captured under the 
same conditions of light and exposure. One blinded pathologist 
performed the analyses using AxioVision software version 4.0 
(Zeiss GmbH, Jena, Germany).
Cartilage thicknesses from the middle part of the femur 
was determined (5 measurements for each articular cartilage 
sample). The measurements were made exclusively in the 
mid-zone, below the surface, in the femoral weight-bearing 
region. This was performed as previous reports have stated 
that in papain-induced models, this part is the most severely 
affected area that exhibits little or no regenerative altera-
tions (26). Cartilage thickness was determined from zones 
1 to 3 (the surface layer to the radial zone) (27).
The relative area of the cartilage and the chondrocyte 
counts were determined using a photomicroscope at a magni-
fication of x400 from each scanned section (28). The relative 
area of the cartilage was calculated using AxioVision software, 
by drawing a circle with a diameter extending from zone 1 
to zone 3. The chondrocytes within the circle were counted. 
This made it possible to obtain relative articular values, the 
total number of chondrocytes in that area, and the chondro-
cytes/mm2. A total of three circular areas were quantified at 
the middle part of the femur for each joint.
The histological architecture of the cartilage was evalu-
ated by two blinded observers using a modification of the 
published mouse scoring system by Chambers et al (29). A 
score of 0 represented normal cartilage; 1 was a roughened 
articular surface and small fibrillations; 2 was fibrillation 
down to the layer immediately below the superficial layer 
(zone 2) and a degree of loss of surface lamina; 3 was the 
loss of surface lamina and fibrillations extending down to 
the calcified cartilage; 4 was major fibrillations and cartilage 
erosion down to the subchondral bone; 5 was major fibrilla-
tions and erosion of ≤80% of the cartilage; and 6 was a loss 
of cartilage of >80%.
Statistical analysis. The quantitative data were represented 
with their mean and standard deviation, while the ordinal 
data were presented through medians. Mean and median 
values were used for the descriptive statistics. For the infer-
ential statistics, normal data distribution was first determined 
using the Kolmogorov-Smirnov test. All the data groups were 
distributed normally and exhibited homogeneity of variance. 
Comparisons between two groups was performed using 
the Student's t‑test. The comparison between the groups of 
mice sacrificed at different times (days 7, 14, and 28) was 
performed using one-way analysis of variance with post-hoc 
Tukey honest significant difference test. Due to the small 
sample size, the Mann-Whitney U test was employed to 
compare the RT-qPCR values. Mann-Whitney U was addi-
tionally used to compare the data of the histological pattern 
of the cartilage, as it was determined through an ordinal scale 
[the Chambers et al (29) scoring system]. Statistical tests 
were performed using IBM SPSS version 20 software (IBM 
Corp., Armonk, NY, USA). A 95% confidence interval was 
used in all the tests, and P<0.05 was considered to indicate a 
statistically significant difference.
Ethics. The trials complied with the national and international 
legal and ethical requirements applicable to pre-clinical 
research. The experimental protocols were approved by 
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the research ethics committee of the Instituto Estatal de 
Cancerología de los Servicios de Salud del Estado de Colima 
(Colima, México). The animals were manipulated according 
to institutional guidelines and the Mexican official norm 
regulating laboratory animal use (no. NOM-062-ZOO-1999), 
in addition to the Guide for the Care and Use of Laboratory 
Animals prepared by the National Academy of Sciences of 
the USA (2011). All animals were sacrificed according to the 
American Veterinary Medical Association 2013 guidelines for 
the sacrifice of animals.
Results
Alterations in expression caused by BIOF2 in human synovial 
fluid cells. Synovial fluid cells exposed to BIOF2 for 48 h 
exhibited increased SOX9 expression by >2-fold (P=0.02) 
and decreased MST1R and OGN expression by 5- and 3-fold, 
respectively (P=0.02). There were no alterations in NOTCH2 
expression compared with unexposed cells (Fig. 1).
In vivo effects on osteoarthritic cartilage thickness. The 
thickness of cartilage in the medial femur sections of 
osteoarthritic model animals was studied in the damaged 
articulation 28 days following the application of BIOF2. In the 
mouse model of induced articular damage, the intra-articular 
administration of saline solution caused no significant altera-
tions in cartilage thickness at 28 days. By contrast, BIOF2 
application caused increased articular thickness from day 14 
of treatment, with a highly significant difference at day 28, 
compared with the saline solution group (P<0.01; Fig. 2A). 
In the mouse model of spontaneous articular damage 
(advanced-age mice) and the OA rabbit model, the cartilage 
of the joints treated with BIOF2 was significantly thicker 
compared with the controls (P=0.001 and P=0.009 for the 
mouse and rabbit models, respectively) (Fig. 2B and C). On 
day 28 following the intra-articular application of BIOF2, 
cartilage thickness increased by 29, 12, and 31%, respec-
tively, compared with the controls in the models of induced 
articular damage in mice, spontaneous damage in mice and 
induced damage in rabbits.
Structure and composition of articular cartilage in the 
mouse models. The articular area, total number of chon-
drocytes and histological architecture of the cartilages were 
determined (Fig. 3). In the papain-induced articular damage 
mouse model, BIOF2 application significantly increased the 
articular area (P=0.01) and the total number of chondrocytes 
(P=0.04) at day 28, compared with the group treated with 
saline solution (Fig. 3A and D). The joints treated with saline 
solution remained unaltered throughout the period following 
treatment. The area and cellularity increased by an average 
of 70% compared with the cartilage treated with saline solu-
tion. In the spontaneous OA mouse model, the results were 
similar, with a 36% increase in area (P=0.04) and a 40% 
increase in cellularity (P=0.009), compared with the control 
group (Fig. 3B and E). It is important to note that the number 
of chondrocytes/mm2 remained unaltered in all the groups 
(Fig. 3C and F).
With respect to the qualitative evaluation of the histological 
architecture of the cartilage, on day 28 following BIOF2 
application there was a significantly decreased grade of 
articular damage, compared with cartilage treated with saline 
solution (Fig. 4). According to the scoring system developed 
by Chambers et al (29), which has a scale from grades 0 to 6 
(0, no damage; 6, >80% loss of cartilage), the medians of the 
groups treated with BIOF2 compared with saline solution were 
2 vs. 3.5 (P=0.02) and 3 vs. 4 (P=0.04) for the spontaneous OA 
and induced OA mouse models, respectively.
Discussion
The present study demonstrated that hyaline cartilage 
regeneration may be induced in vivo via the intra-articular 
application of the novel bioactive formulation BIOF2. This 
was observed in three different animal models. In a 28-day 
follow-up of one of the animal models it was observed that 
the thickness of the cartilage and the number of chondrocytes 
began to increase slightly on day 14 post-treatment. However, 
the most important histological alterations occurred between 
days 14 and 28, and the latter day was when all the morpho-
metric parameters were highly significant and beneficial 
in regard to treatment with BIOF2, compared with saline 
solution application. It was notable that the increase in thick-
ness and articular area was accompanied by a proportional 
increase in cellularity (chondrocytes/mm2 was unaltered). 
This demonstrated that cartilage growth was not solely due 
to extracellular matrix growth.
In addition, upon analyzing the histological architec-
ture, the joints treated with BIOF2 exhibited a lower grade 
of damage compared with the controls, suggesting repair 
towards a normal joint morphology. An additional relevant 
aspect in relation to the BALB/c mouse animal models, 
compared with their controls, was the fact that there was a 
greater increase in cartilage thickness (29%) in the induced 
Figure 1. Expression level alterations caused by BIOF2 in exposed and unex-
posed cells, assayed by reverse transcription-quantitative polymerase chain 
reaction analysis. In the presence of BIOF2, SOX9 expression increased and 
MST1R and OGN levels decreased. NOTCH2 remained unaltered. Data 
expressed as alterations (log-scale) in mRNA abundance were ratios of 
mRNAs estimated in BIOF2‑exposed synovial fluid cells, compared with 
unexposed synovial fluid cells under the same conditions. GAPDH was used 
as an internal control to normalize the target RNA. The graph exhibits the 
mean and standard deviation of an experiment conducted in quadruplicate at 
48 h following exposure. *P<0.05 vs. unexposed cells. SOX9, transcription 
factor SOX-9; NOTCH2, neurogenic locus notch homolog protein 2; MST1R, 
macrophage stimulating protein receptor; OGN, mimecan.
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articular damage model in young mice compared with the 
advanced‑age mouse model (12%) at post‑treatment day 28. 
This concurs with clinical findings that have demonstrated 
that current techniques for damaged cartilage repair appear 
to produce better results in young patients (30). This may be 
relevant to the suggested dosage for young or elderly patients 
in future clinical trials.
The mechanism through which BIOF2 may regenerate 
articular cartilage was examined at the molecular level via 
experiments performed on human synovial fluid cells. BIOF2 
caused an increase in the expression of SOX9, a transcription 
factor that is essential for chondrocyte differentiation and 
cartilage formation (31). SOX9 serves a notable role in the 
development and maintenance of the chondrogenic phenotype. 
One previous study demonstrated that SOX9 expression was 
relatively high in normal cartilage, although its transcript 
levels were substantially decreased in OA, accompanied by 
degradation of the extracellular matrix; the study addition-
ally suggested that a reduction of SOX9 transcript levels in 
osteoarthritic chondrocytes may be responsible for such loss 
of the extracellular matrix (32). Effective chondrogenesis and 
inhibition of bone morphogenetic protein 2-induced osteo-
genesis and endochondral ossification have additionally been 
demonstrated to be achieved by directing MSCs towards the 
chondrocyte lineage with SOX9 (33). A further hypothesis for 
correcting OA is the overexpression of SOX9 through gene 
therapy, possibly combined with cell therapy (34,35). This 
indicates that the increase in SOX9 by BIOF2 is a consistent 
Figure 2. Evaluation of femoral articular cartilage thickness in three different animal models. (A) Mouse model of papain‑induced articular damage. Saline 
solution did not cause alterations in the cartilage during the analysis period; BIOF2 produced a significant increase in thickness at 14 and 28 days following 
application. (B) Advanced-age mouse model of spontaneous articular damage. (C) Rabbit model of papain-induced articular damage. Treatment with BIOF2 
produced a significant increase in articular thickness in the advanced‑age mice and the rabbits, compared with respective control groups. The graph exhibits 
the mean ± standard deviation. *P<0.01 vs. saline.
Figure 3. Relative area of the femoral articular cartilage and number of chondrocytes. In the mouse model of papain-induced articular damage, only the 
post‑treatment day 28 evaluation of the BIOF2 treated group exhibited a statistically significant increase in (A) relative area of cartilage and (B) number 
of chondrocytes. (C) There was no significant difference in the number of chondrocytes/mm2. Saline solution did not produce any significant alterations in 
the cartilage during the time of evaluation. In the advanced-age mouse model of spontaneous articular damage evaluated on post-treatment day 28, BIOF2 
produced a significant increase in (D) the area and (E) the number of chondrocytes compared with the control group. (F) There was no significant difference 
in the number of chondrocytes/mm2. The graphs exhibit the mean ± standard deviation. *P<0.05 vs. saline.
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mechanism with the therapeutic effect observed in the present 
study.
The results of the present study demonstrated that 
BIOF2 caused a decrease in OGN and MST1R expression. 
OGN has been reported to be elevated in OA synovial fluid 
samples and may induce the mineralization and calcification 
of cartilage (37). Additionally, MST1R has been previously 
identified to be associated with osteoclastogenesis, osteolysis 
and inflammation (38,39). The decreased expression of these 
genes is consistent with a therapeutic effect of BIOF2 on OA. 
Although previous studies have demonstrated that the Notch 
pathway is active during chondrogenesis (40,41), the present 
study identified no increase in NOTCH2. However, NOTCH2 
expression was measured only once, and the possibility of its 
modification at another evaluation time may not be excluded, 
which is a limitation of the present analysis. Gene expression 
alterations (including SOX9 and cytokines) in the joint tissue 
following in vivo application of BIOF2 are an important aspect 
to study in future experiments in animal models or in clinical 
trials.
The results of the present study have led to the proposal 
of an innovative strategy to clinically repair osteoarthritic 
lesions through BIOF2-induced cartilage regeneration. This 
therapeutic strategy is novel and different from other OA 
treatment alternatives, including viscosupplementation, 
gene therapy or cell therapy. The novel strategy is based on 
modifying the intra-articular microenvironment to stimulate 
articular regeneration, by generating molecular and morpho-
logical alterations in synovial fluid cells and chondrocytes. 
The synovium is considered to be a candidate source of cells 
for cartilage. Compared with MSCs from other sources, 
synovium-derived stem cells have a higher capacity for chon-
drogenic differentiation (42). Fibrous synovium cells (with the 
typical bipolar configuration), including the cells cultivated 
in the present study, have previously been observed to release 
large numbers of MSCs (43). It is likely that BIOF2 produces 
molecular alterations, including SOX9 upregulation, in syno-
vial MSCs that favor SOX9 migration to the cartilage and 
differentiation into chondrocytes. In addition, BIOF2 appears 
to generate SOX9 elevation in chondrocytes, thus reversing the 
alterations associated with OA.
There are numerous problems associated with current OA 
treatment strategies. In advanced disease cases, the recom-
mendation is to substitute the joint with a prosthesis. However, 
the surgical treatment is costly (5), with long waiting lists, 
and it may be risky for elderly patients or those with comor-
bidities (6). Conservative treatment with oral medications, 
including glucosamine, chondroitin sulfate, methylsulfonyl-
methane or collagen hydrolysates, has exhibited limited or no 
benefit. Intra‑articular injections of different substances are 
additionally being evaluated. The intra-articular administra-
tion of corticosteroids produces a short-term improvement. 
However, the repeated use of corticosteroids may facilitate 
tissue atrophy, joint destruction or cartilage degeneration (44). 
Hyaluronic acid derivatives produce apparent effectiveness 
5‑13 weeks following treatment. They are inferior to steroids 
in the short-term, although they provide greater improvement 
over an increased length of time (45). Platelet-rich plasma is 
under consideration as an innovative and promising tool with 
an effectiveness pattern comparable to the intra-articular 
administration of hyaluronic acid (7). Stem cell therapy is 
an additional strategy whose aim is to support the process 
of self‑healing of the knee joint cartilage damage resulting 
from OA symptoms (1). The intra-articular application of 
stem cells, facilitating their differentiation into chondro-
cytes, is a process that includes the separation of the cells by 
centrifugation and other purification steps, with the aim of 
increasing cartilage buildup. Clinical data on the effective-
ness of stem cell therapy remains insufficient and certain 
authors have expressed concerns regarding the issues of 
dosage, intervention timing, mode, route of delivery and the 
type of stem cells in clinical studies (8,9). It is hypothesized 
that the BIOF2-induced regeneration strategy has the poten-
tial to ameliorate the problems or limitations of current OA 
treatments.
In conclusion, the application of BIOF2 was effective for 
the treatment of OA in animal models, possibly as a result of 
increased SOX9 expression in articular cells. This regenera-
tion strategy merits further study as a realistic research focus 
in the near future, particularly in clinical trials.
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Figure 4. Microscopic images from the medial femur sections of model 
mice on treatment day 28. (A) Papain-induced osteoarthritis treated with 
BIOF2; small and isolated fibrillations are observed over the articular matrix 
(grade 1). (B) Papain-induced osteoarthritis treated with saline solution; 
fibrillation is observed immediately below the superficial layer, in addition to 
the loss of the lamina surface within calcification spots of articular cartilage 
(grade 2). (C) Advanced-age spontaneous osteoarthritis treated with BIOF2; 
small and isolated fibrillations are observed in the articular matrix (grade 1). 
(D) Advanced-age spontaneous osteoarthritis treated with saline solution; a 
deflated and irregular articular surface (indicated by an arrow), in addition to 
extended fibrillation and calcification spots, are observed (grade 3). Cartilage 
thickness of medial femur sections is exhibited in A and B. Hematoxylin 
and eosin staining; magnification, x200. Lesions graded according to the 
Chambers et al (29) scoring system.
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